These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 16098411)

  • 101. Adjustment of inpatient care reimbursement for nursing intensity.
    Welton JM; Zone-Smith L; Fischer MH
    Policy Polit Nurs Pract; 2006 Nov; 7(4):270-80. PubMed ID: 17242392
    [TBL] [Abstract][Full Text] [Related]  

  • 102. The impact of using different costing methods on the results of an economic evaluation of cardiac care: microcosting vs gross-costing approaches.
    Clement Nee Shrive FM; Ghali WA; Donaldson C; Manns BJ
    Health Econ; 2009 Apr; 18(4):377-88. PubMed ID: 18615835
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Cost unit accounting based on a clinical pathway: a practical tool for DRG implementation.
    Feyrer R; Rösch J; Weyand M; Kunzmann U
    Thorac Cardiovasc Surg; 2005 Oct; 53(5):261-6. PubMed ID: 16208610
    [TBL] [Abstract][Full Text] [Related]  

  • 104. An economic model of one-level lumbar arthroplasty versus fusion.
    Guyer RD; Tromanhauser SG; Regan JJ
    Spine J; 2007; 7(5):558-62. PubMed ID: 17588819
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.
    Carrington M; Stewart S
    Int J Cardiol; 2008 Jun; 127(1):51-6. PubMed ID: 17586072
    [TBL] [Abstract][Full Text] [Related]  

  • 106. [How to calculate the budget of an anaesthetic or intensive care department from revenues of g-DRGs].
    Schütt S; Gräbner B; Saathoff H; Martin J; Vagts DA
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2007 Nov; 42(11):834-9. PubMed ID: 18040939
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Accounting for the costs of quality.
    Suver JD; Neumann BR; Boles KE
    Healthc Financ Manage; 1992 Sep; 46(9):28-31, 33-7. PubMed ID: 10145679
    [TBL] [Abstract][Full Text] [Related]  

  • 108. The doctor, the patient, & the DRG.
    Wasserman J
    Hastings Cent Rep; 1983 Oct; 13(5):23-5. PubMed ID: 6417052
    [TBL] [Abstract][Full Text] [Related]  

  • 109. [Does DRG improve or impair the quality of care?].
    Lüngen M; Lauterbach KW
    Chirurg; 2001 Oct; 72(10):suppl 270-3. PubMed ID: 11715627
    [No Abstract]   [Full Text] [Related]  

  • 110. Cost accounting for end-of-life care: recommendations to the field by the Cost Accounting Workgroup.
    Seninger S; Smith DG;
    J Health Care Finance; 2004; 30(4):79-92. PubMed ID: 15682955
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Pricing health services for purchasers--a review of methods and experiences.
    Waters HR; Hussey P
    Health Policy; 2004 Nov; 70(2):175-84. PubMed ID: 15364147
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Effects of a mandatory DRG payment system in South Korea: Analysis of multi-year nationwide hospital claims data.
    Choi JW; Kim SJ; Park HK; Jang SI; Kim TH; Park EC
    BMC Health Serv Res; 2019 Oct; 19(1):776. PubMed ID: 31666066
    [TBL] [Abstract][Full Text] [Related]  

  • 113. DRG prospective payment systems: refine or not refine?
    Hafsteinsdottir EJ; Siciliani L
    Health Econ; 2010 Oct; 19(10):1226-39. PubMed ID: 19780065
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Cost cutting in health systems without compromising quality care.
    Clark DD; Savitz LA; Pingree SB
    Front Health Serv Manage; 2010; 27(2):19-30. PubMed ID: 21449483
    [TBL] [Abstract][Full Text] [Related]  

  • 115. The high price of technology: factors affecting hip implant costs.
    Mendenhall S
    Healthc Financ Manage; 1988 Aug; 42(8):42-4, 46, 48-51. PubMed ID: 10312572
    [TBL] [Abstract][Full Text] [Related]  

  • 116. How innovative are pharmaceutical innovations?: the case of medicines financed through add-on payments outside of the French DRG-based hospital payment system.
    Gridchyna I; Aulois-Griot M; Maurain C; Bégaud B
    Health Policy; 2012 Jan; 104(1):69-75. PubMed ID: 22136813
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Device therapy and hospital reimbursement practices across European countries: a heterogeneous scenario.
    Boriani G; Burri H; Mantovani LG; Maniadakis N; Leyva F; Kautzner J; Lubinski A; Braunschweig F; Jung W; Lozano IF; Fattore G
    Europace; 2011 May; 13 Suppl 2():ii59-65. PubMed ID: 21518752
    [TBL] [Abstract][Full Text] [Related]  

  • 118. [Structure of the Australian system of 'Diagnosis Related Groups' regarding cardiovascular diseases and corresponding cost weights in Germany].
    Wietholt D; Köpfer T; Paul K; Gässler A; Bruch L; Kleber FX
    Z Kardiol; 2003 Aug; 92(8):619-26. PubMed ID: 12955408
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Materials management's role in product line development.
    Linden R
    Hosp Mater Manage; 1986 Jun; 11(6):8-12. PubMed ID: 10311583
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Lifting the weight of a diagnosis-related groups family change: a comparison between refined and non-refined DRG systems for top-down cost accounting and efficiency indicators.
    Zlotnik A; Cuchi MA; Pérez Pérez MC
    Health Inf Manag; 2015; 44(2):12-9. PubMed ID: 26157082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.